ProQR Therapeutics NV Submits CTA for AX-0810 to Target Cholestatic Diseases, Showcasing Progress in CNS Applications at Upcoming RNA Editing Summit

Reuters07-28

ProQR <a href="https://laohu8.com/S/LENZ">Therapeutics</a> NV Submits CTA for AX-0810 to Target Cholestatic Diseases, Showcasing Progress in CNS Applications at Upcoming RNA Editing <a href="https://laohu8.com/S/SMMT">Summit</a>

ProQR Therapeutics NV has announced a significant milestone in their ongoing development of RNA therapies. The company has submitted a Clinical Trial Application $(CTA.UK)$ for their product AX-0810, which targets NTCP for the treatment of cholestatic diseases. This submission marks a key step forward for ProQR as they continue to advance their proprietary Axiomer™ RNA editing technology platform. The news comes ahead of ProQR's upcoming presentation at the RNA Editing Summit in Boston, where further details on their CNS applications and Rett program will be discussed.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ProQR Therapeutics NV published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW1001119801-en) on July 28, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2554779650?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-28 20:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2554779650","market":"nz","top_or_hot":-1,"title":"ProQR Therapeutics NV Submits CTA for AX-0810 to Target Cholestatic Diseases, Showcasing Progress in CNS Applications at Upcoming RNA Editing Summit","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      ProQR <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> NV Submits CTA for AX-0810 to Target Cholestatic Diseases, Showcasing Progress in CNS Applications at Upcoming RNA Editing <a href=\"https://laohu8.com/S/SMMT\">Summit</a>\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        ProQR Therapeutics NV has announced a significant milestone in their ongoing development of RNA therapies. The company has submitted a Clinical Trial Application <a href=\"https://laohu8.com/S/CTA.UK\">$(CTA.UK)$</a> for their product AX-0810, which targets NTCP for the treatment of cholestatic diseases. This submission marks a key step forward for ProQR as they continue to advance their proprietary Axiomer™ RNA editing technology platform. The news comes ahead of ProQR's upcoming presentation at the RNA Editing Summit in Boston, where further details on their CNS applications and Rett program will be discussed.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ProQR Therapeutics NV published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW1001119801-en) on July 28, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ProQR Therapeutics NV Submits CTA for AX-0810 to Target Cholestatic Diseases, Showcasing Progress in CNS Applications at Upcoming RNA Editing Summit</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nProQR Therapeutics NV Submits CTA for AX-0810 to Target Cholestatic Diseases, Showcasing Progress in CNS Applications at Upcoming RNA Editing Summit\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-07-28 20:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      ProQR <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> NV Submits CTA for AX-0810 to Target Cholestatic Diseases, Showcasing Progress in CNS Applications at Upcoming RNA Editing <a href=\"https://laohu8.com/S/SMMT\">Summit</a>\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        ProQR Therapeutics NV has announced a significant milestone in their ongoing development of RNA therapies. The company has submitted a Clinical Trial Application <a href=\"https://laohu8.com/S/CTA.UK\">$(CTA.UK)$</a> for their product AX-0810, which targets NTCP for the treatment of cholestatic diseases. This submission marks a key step forward for ProQR as they continue to advance their proprietary Axiomer™ RNA editing technology platform. The news comes ahead of ProQR's upcoming presentation at the RNA Editing Summit in Boston, where further details on their CNS applications and Rett program will be discussed.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ProQR Therapeutics NV published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW1001119801-en) on July 28, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4588","symbol_name":"碎股","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250728:nNDLc7bnNj:1","article_id":"2554779650","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2554779650","pubTimestamp":1753704039,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"ProQR Therapeutics NV Submits CTA for AX-0810 to Target Cholestatic Diseases, Showcasing Progress in CNS Applications at Upcoming RNA Editing Summit. ProQR Therapeutics NV has announced a significant milestone in their ongoing development of RNA therapies. The company has submitted a Clinical Trial Application  for their product AX-0810, which targets NTCP for the treatment of cholestatic diseases. This submission marks a key step forward for ProQR as they continue to advance their proprietary Axiomer RNA editing technology platform. The news comes ahead of ProQR's upcoming presentation at the RNA Editing Summit in Boston, where further details on their CNS applications and Rett program will be discussed.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4588":"碎股","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","PRQR":"ProQR Therapeutics N.V.","BK4112":"金融交易所和数据","BK4585":"ETF&股票定投概念","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","BK4139":"生物科技","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","NDAQ":"纳斯达克OMX交易所","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC"},"translate_title":"ProQR Therapeutics NV提交针对胆汁淤积性疾病的AX-0810 CTA，在即将举行的RNA编辑峰会上展示CNS应用进展","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NDAQ":0.9,"PRQR":0.9},"content_text":"ProQR Therapeutics NV Submits CTA for AX-0810 to Target Cholestatic Diseases, Showcasing Progress in CNS Applications at Upcoming RNA Editing Summit\n\n\n        ProQR Therapeutics NV has announced a significant milestone in their ongoing development of RNA therapies. The company has submitted a Clinical Trial Application $(CTA.UK)$ for their product AX-0810, which targets NTCP for the treatment of cholestatic diseases. This submission marks a key step forward for ProQR as they continue to advance their proprietary Axiomer™ RNA editing technology platform. The news comes ahead of ProQR's upcoming presentation at the RNA Editing Summit in Boston, where further details on their CNS applications and Rett program will be discussed.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ProQR Therapeutics NV published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW1001119801-en) on July 28, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2554779650","isCrawlerRequest":true}